Breaking up sedentary time to improve glucose control in people at risk for type 2 diabetes
Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes
This study tests if taking short breaks for 5-minute physical activities can help people at risk for type 2 diabetes control their blood sugar better than just doing longer workouts.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 66 (estimated) |
| Ages | 18 Years to 64 Years |
| Sex | All |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 1 site (Aurora, Colorado) |
| Trial ID | NCT05041491 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of interrupting prolonged sedentary behavior with short bouts of physical activity on glucose control in individuals at risk for developing type 2 diabetes. Participants will engage in brief, 5-minute physical activity sessions throughout the day, rather than traditional longer exercise sessions. The goal is to determine if this novel approach can lead to better glycemic outcomes compared to standard physical activity recommendations. The study will include individuals who meet specific criteria for pre-diabetes and sedentary behavior.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-64 with pre-diabetes and high sedentary behavior, as defined by specific glucose levels and physical activity metrics.
Not a fit: Patients who are already highly active or have significant comorbidities that limit physical activity may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve glucose control and reduce the risk of developing type 2 diabetes in at-risk populations.
How similar studies have performed: Preliminary data suggest that breaking up sedentary time may improve glycemia, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female * BMI of 18.5-40 kg/m2 and weight stable over the previous 6 months. * Age, 18-64 years old. * Fasting glucose of 100-125 mg/dL or fasting HbA1c of 5.7-6.4%, or 2h OGTT blood glucose of 140-199mg/dL based on the American Diabetes Association criteria for pre-diabetes. Fasting glucose, HbA1c and OGTT results ordered by the participant's provider within 3-months of the screening visit will be accepted, provided they fall within the measurement of error range established by the institution's lab standards. Additionally, consistent use of Metformin (1 year) to prevent prediabetes from developing diabetes will be accepted. * Less than 150 minutes of moderate-to-vigorous physical activity (MVPA) per week and more than 6 hours of sitting time per day, as self-reported by the volunteers using the International Physical Activity Questionnaire (IPAQ). * Less than 6500 of steps per day as measured by a pedometer over 5 days (at least 1 weekend day). * Passing medical and physical screening, and analysis of blood and urine screening samples. * Low-moderate caffeine use (\<3 cups/day). * Agree to refrain from any other structured exercise than the physical activity prescribed in each arm of the study. * Agree to eat control diets for 3 days before and during the Clinical and Translational Research Center (CTRC) visits; * Agree to refrain from taking any over-the-counter (including nonsteroidal anti-inflammatory drugs) or prescribed medication (apart from oral contraceptives) for 3 days prior to the inpatient CTRC visits; * Agree to wear a Fitbit® activity monitor and upload data on the website on a daily basis for the whole duration of the study. * Agree to follow the physical activity interventions and to be randomly assigned to one of the two arms of the study. * Agree to complete all the study procedures. Exclusion Criteria: * Pregnancy, breast-feeding or post-menopause for women. * Being considered unsafe to participate as determined by the study physician. * Ever having a history of systemic, psychiatric, neurological disease, or drug and alcohol abuse. * History of cardiovascular disease, diabetes, uncontrolled hypertension, untreated thyroid, renal, hepatic diseases, dyslipidemia or any other medical condition affecting weight or lipid metabolism. * Being positive for human immunodeficiency virus or hepatitis B or C. * Taking medications affecting weight, triglycerides, energy intake/energy expenditure, or sleep in the last 3 months. * Having abnormal blood chemistry and/or hematology as deemed significant by the study physician. * Being a smoker or having been a smoker in the 3 months prior to their screening visit. * Having donated over 400 mL of blood within 3 months (90 days) of screening for the study; * Working night shifts within 1 month of and throughout the study. * Not completing the trial days of BREAK and ONE during the screening period to assess the willingness and ability of the participant to perform each of the interventions.
Where this trial is running
Aurora, Colorado
- University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States (Recruiting)
Study contacts
- Principal investigator: Audrey Bergouignan, PhD — University of Colorado, Denver
- Study coordinator: Patricia Smith, MS, RDN
- Email: trish.smith@cuanschutz.edu
- Phone: 303.724.6821
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.